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The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
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Trent DEC, chaired by Professor Sir David Hull. 
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1 
EXECUTIVE SUMMARY 
 
 
Heart failure is a significant health problem in the UK and is estimated to consume about 
1% of the NHS budget. It causes high morbidity and mortality. Treatment with Angiotensin- 
Converting Enzyme (ACE) Inhibitors can reduce symptomatic deterioration and 
hospitalisation, delay death, and improve quality of life. The weight of evidence indicates 
that the effects on reduced hospitalisation mean that the health gain associated with the use 
of ACE Inhibitors can be achieved with potential resource savings. Research has indicated 
that the benefits of ACE Inhibitors are class and not drug specific and, as such, cheaper 
ACE Inhibitors are expected to be more cost-effective than more expensive ones. 
 
This paper addresses two primary questions: 
 
1. Can the wider use of ACE Inhibitors lead to NHS resource savings (real or notional) 
 through reduced demand for in-patient hospitalisations?  
 
2. Can savings be made by substituting more expensive ACE Inhibitors with less 
 expensive brands for all conditions for which ACE Inhibitors are prescribed (including 
 hypertension and incipient heart failure following myocardial infarction)? 
 
Question 1 
 
Analysis addressing the first issue indicates that, in an average health authority of 
population 500,000, extending the use of ACE Inhibitors to treat all patients who could 
benefit would prevent an estimated 42 premature deaths per annum and could save a 
potential £400,000 in ‘year one’ with even greater savings expected in subsequent years. 
The modelled bed day savings are estimated at around 13 beds for this population. 
Modelling excludes potential resource savings from any reduced demand for GP and out-
patient attendances. Sensitivity analysis indicates large margins for error in input 
assumptions before the modelled potential savings are eliminated. However, the paper 
notes that savings are largely potential rather than real, in that it can be difficult to convert 
in-patient bed day savings into actual cash savings. 
 
Certain types of chronic heart failure (e.g. due to left ventricular dysfunction) and early 
forms of heart failure can be difficult to detect in the community and can lead to significant 
amounts of over-diagnosis and inappropriate prescribing of ACE Inhibitors and diuretics. 
The paper acknowledges the need for good access to echocardiography to improve 
2 
diagnosis of heart failure, thus preventing over-prescribing of diuretics and ACE Inhibitors. 
The analysis includes the cost of echocardiography, but ignores potential savings from 
more appropriate prescribing, giving further weight to the likelihood of a potential net 
resource saving result. Other potential costs, such as induced demand for 
echocardiography and extended life treatment, are thought to be well within the margins of 
the sensitivity analyses used. 
 
The paper acknowledges, but does not explore explicitly, the potential costs of increased 
renal failure due to combination therapy of ACE Inhibitors with Non-Steroidal Anti-
inflammatory Drugs (NSAIDS) in the elderly population and a theoretical risk for patients 
with unilateral renal artery stenosis. 
 
A policy of more extensive prescribing of ACE Inhibitors for the treatment of heart failure 
would need a co-ordinated and managed implementation. The Sheffield Framework for 
Appropriate Care Throughout Sheffield (FACTS) project and the Promoting Action on 
Clinical Effectiveness (PACE) project in North Derbyshire are both well placed to contribute 
to this. Implementation costs are likely to be substantial, though not prohibitive. Such 
implementation costs and the costs of diagnostic tests may require pump-priming monies in 
some districts. 
 
Question 2 
 
The second part of the paper indicates a wide range of estimated potential savings and 
costs of switching between brands of ACE Inhibitors. The analysis required a number of 
assumptions to allow for the paucity of appropriately detailed prescribing data. The weight 
of evidence is that cost savings could be made, but that these may not be substantial. 
Energies might be better directed at ensuring that new patients are initiated on to the less 
expensive formulations. 
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1. INTRODUCTION 
 
1.1 Background 
 
Heart failure is a syndrome usually caused by myocardial or valvular dysfunction. The typical 
symptoms include shortness of breath, tiredness and signs of fluid retention with ankle 
swelling and crepitations in the chest. However, these are the signs of established heart 
failure. Many patients may have demonstrable evidence of left ventricular dysfunction (LVD) 
or clinically transient heart failure, for example, following a myocardial infarction, without 
developing overt signs of heart failure for months or years. 
 
1.2 Prognosis and Mortality 
 
Published research shows a range of mortality rates. For example, Framingham data
1 
suggest two year mortality rates of 37% and 38% for men and women respectively. At six 
years, these mortality rates increase to 82% and 67% respectively, four to eight times that of 
the general population. Using the New York Heart Association (NYHA) severity scale, the 
annual death rate with respect to severity is estimated to be  Grade I - 7.5%, Grade II -
12.5%, Grade III - 15%, and Grade IV - 40%.
2 
 
 
In a study in a district general hospital, Parameshwar and colleagues
3
 noted that 4.9% of 
medical admissions had heart failure. Of these, 44% died within the first year (30% whilst in 
hospital) and 41% had coronary heart disease (CHD) as the aetiology of their heart failure. 
The average length of stay (LOS) in hospital was 16.7 days, with a range of 1 to 33 days. 
Other studies note death rates of 10-20% for mild heart failure and 40-60% for severe heart 
failure within the first year.
4,5
 
 
1.3  Prevalence and Incidence 
 
The size of the problem is difficult to quantify. Dargie et al.
6 
state that there are few data on 
causes, prevalence and incidence with no reliable data on consultations for definite heart 
failure in general practice. This is because studies of prevalence and incidence use different 
criteria for diagnosis and, generally, base the estimates on either self-reported or clinical 
diagnoses. O’Connell and Moore express similar sentiments.
7
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1.3.1 Prevalence  
Prevalence figures for the general population range from 0.091%,
3
 0.4%,
8
 1.5% to 3%,
9
 and 
0.88% to 1.2%.
10
 In a small practice-based study, using positive echocardiography as the 
diagnostic criterion, a prevalence rate of 0.84% with 95% confidence intervals (CI) of 0.72% 
to 0.98% was found in a general population.
11
 Age specific figures range from 2%
12
 for 25-
74 year olds, 2.1% for heart failure in 50 year olds and 13% for heart failure in 67 year 
olds,
13  
to varying rates within different age groups - 0.8% (50-59), 2.3% (60-69), 4.9% (70-
79) and 9.1% (80-89).
1  
Smith states that most of the studies in the United States suggest a 
prevalence of 1% in the general population.
14
 McMurray
 
estimated that there were about 
570,000 people with heart failure in the UK (equivalent to about 1% prevalence).
15 
Of those 
with definite heart failure, studies suggest different proportions for those meeting the NYHA 
criteria of severity, with Grade IV being the most severe; e.g.: 35% NYHA I, 35% II, 25% III, 
5% IV,
2
 and 50% NYHA I, 25% II, 15% III, 10% IV.
16 
 
1.3.2  Incidence  
As with prevalence, the estimates for incidence vary widely. In a Finnish study
17 
the 
incidence in the 45-74 year age group was 0.4% per annum in men and 0.1% per annum in 
women. The Framingham study
1 
suggested incidence rates of 0.3% per annum for men and 
0.2% per annum in women aged between 35 and 64 years and 1% and 0.8% per annum 
respectively for 65 - 94 year old men and women. Similar figures were derived by 
Erickson
13
, suggesting an overall incidence of 0.55% per annum for 50 to 67 year olds.
 
 
1.4 Size of Problem in a ‘Typical’ District 
Reported estimates of prevalence of heart failure range from as low as 0.09%
3
 to 3%
14
 with 
a commonly used average prevalence rate of 1%
14
. For a ‘typical’ district of 500,000 
population, these rates imply estimates of numbers of affected population ranging from 455 
to 15,000, with a central estimate of 5,000 heart failure patients.  
 
Published age-specific incidence rates applied to a population of 500,000 with a Standard 
European demographic profile produce the following estimates of incidence:- 
 
Finnish study
17
     370  for 45 to 74 years of age; 
Erickson
13
     825  for 50 to 67 years of age; 
Framingham
1
             1,000  for 35 to 74 years of age. 
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In a study of heart failure patients in North Derbyshire, which has a demographic profile 
similar to the Standard European profile and a higher than average mortality rate from 
coronary heart disease, the following data were recorded: 
 
 92% of heart failure patients were diagnosed clinically; 
 16% had had an echocardiogram; 
 45% were taking Angiotensin-Converting Enzyme (ACE) Inhibitors - 57% of these had 
been started in hospital; 
 54% of those taking ACE Inhibitors had urea and electrolytes (U&E) checked at the 
beginning of therapy but only 39% of these were rechecked within the first six weeks of 
therapy; 
 Average hospital length of stay was 12.5 days (median 6.5). 
 
North Derbyshire Health Authority collated this information as part of a King’s Fund 
Promoting Action on Clinical Effectiveness (PACE) project, using heart failure as the 
example, (see Appendix 1). 
 
In a  study in the Kensington and Chelsea Health Authority District
18
: 
 
 47% of patients diagnosed clinically with heart failure were taking ACE Inhibitors;  
 31% had had an echocardiogram. 
 
These studies demonstrate, as with many other treatments, that not all patients who could 
benefit from a given therapy do in fact receive such treatment. The reasons for this would 
need to be researched, but they are likely to include: failure to follow-up appropriate patients 
by GPs (which may be a result of lack of time and/or the resources to spend trawling patient 
notes in order to identify suitable patients); failure to attend on the part of patients; and lack 
of appreciation of the benefits and the effectiveness of ACE Inhibitors. 
 
McMurray and colleagues
15
 estimated the total cost of treating heart failure in the UK to be 
£360m in 1990/91 including:- 
 
Hospitalisation costs  59.5% 
Investigations  16% 
Drug Therapy  7.5% 
 
 6 
This £360m represented over 1% of the total NHS budget.  
 
Wheeldon and colleagues,
11
 in a retrospective study of patient records over a period of five 
years between 1985 and 1990, found that heart failure patients admitted to a coronary care 
unit, a general medical ward or a geriatric ward, generated 81, 14 and 66 GP visits per 
patient respectively. For patients seen in an out-patient department in cardiology, general 
medicine or geriatrics there were 22, 7 and 266 GP visits respectively. In estimating the cost 
of heart failure to the NHS, McMurray
15
 allowed for four GP consultations per patient per 
year. 
 
In summary, heart failure is a sizeable problem affecting over half a million people in the UK 
and accounting for considerable use of NHS resources in terms of bed usage, physician 
time and drug usage. It is a serious disease with a greater than 50%  mortality after five 
years. 
 7 
2. USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN THE 
 TREATMENT OF HEART FAILURE: SUMMARY OF EVIDENCE OF 
 EFFECTIVENESS 
 
ACE Inhibitors were introduced initially in the early eighties. Originally, they were used for 
the treatment of hypertension and overt congestive cardiac failure, but are now also used for 
incipient heart failure as occurs particularly following an acute myocardial infarction. In the 
early days, it was advised that commencement of treatment should be in hospital under 
consultant supervision. This was because of the potential for causing or exaggerating 
hypertension and deteriorating renal function. They may also cause potassium retention in 
those patients with renal impairment or taking diuretics. However, hospital admission is no 
longer thought to be justified for the majority of cases and initiation of treatment in primary 
care is acceptable provided that there is careful monitoring of renal function. Following the 
initial development of captopril, there are now a number of preparations on the market. More 
recently, there has been the emergence of Angiotensin II inhibitors. These are thought to 
have similar actions to the earlier drugs but with fewer side effects, particularly with respect 
to cough development. Their efficacy in heart failure has not yet been established.  
 
2.1 Clinical Efficacy of ACE Inhibitors 
 
Several studies demonstrate the clinical efficacy of ACE Inhibitors in different conditions: in 
primary heart failure;
19,20,21,22,4 
for patients with LVD with symptoms of heart failure;
23 
for 
patients with poor LVD but without symptoms of heart failure;
24,25 
for patients with symptoms 
of heart failure following myocardial infarction etc;
5,26,27 
for all patients after myocardial 
infarction;
28,29
 and in hypertension.
30,31  
Some key trials are summarised in Table 1. The 
efficacy is confirmed by Garg’s meta-analysis.
32
 However, in a meta-analysis of eleven 
randomised controlled trials, Nony et al.
33
 failed to show benefit in patients with heart failure 
not related to (ischaemic) CHD. There are a number of consensus statements and 
guidelines recommending the use of ACE Inhibitors in heart failure.
34,35,36  
However, there is 
evidence of poor management in patients who are diagnosed as having heart failure, both in 
terms of inadequate diagnosis
17,11
 and, of those who are diagnosed, inadequate treatment.
37  
In one study, only 32% of those suspected of having heart failure had objective evidence of 
LVD,
17
 and up to 47% (37% in males and 73% in women) of diagnoses were erroneous in 
work elsewhere.
11
 Another study found that only 56% of those prescribed diuretics by their 
GP for presumed heart failure, fulfilled the criteria for diagnosis of congestive cardiac failure. 
Of these, 74% had been referred to hospital for investigation. However, only 31% of these 
 8 
had had an echocardiogram. This means that only about 14% of all those treated for 
congestive cardiac failure had had a definitive investigation and diagnosis.
37
 
 
Table 1   Use of ACE Inhibitors in Heart Failure 
 
Study Number of 
Patients 
 
 
 
 
P            T  
Patient Group  Drug 
Used 
Length 
of 
Study 
Follow- 
up 
 
 
Changes 
in Overall 
Mortality 
Rates 
 
 
P        T 
Changes in 
Rates of 
Hospitalisation 
 
 
 
P               T 
Cohn V-Heft II
21 
Data from the 
study used to 
compare with 
results from V-
Heft I 
38
 
273      403 
Men,  18-75 
years old with 
symptomatic 
heart failure  
Left Ventricular 
(LV) ejection 
fraction  <0.45 
Enalapril 
20 mg 
daily 
4 years 54%  42% 
mortality 
ARR
*
 12% 
at 4 years 
 
       
CONSENSUS
22
 126      127 Men and women. 
Clinical diagnosis 
of severe (NYHA 
IV) heart failure 
Enalapril
5-40mg 
daily 
Average 
6 
months 
52%  36% 
mortality 
ARR 16% 
at 1 year  
 
       
SOLVD
4
 1284  1285 Men and women. 
Symptomatic 
heart failure LV 
ejection fractions 
< 0.35 
Enalapril
2.5-10mg 
twice 
daily 
Average 
42 
months 
40%  35%    
mortality 
ARR 5% 
at 4 years 
 64%      54% 
ARR 10% in 
hospitalisation 
rate without 
death 
       
Captopril 
Digoxin 
Multicenter 
Research 
Group
19
 
100     104 
Men and women 
<75 years old. 
Symptomatic 
heart failure 
LV ejection 
fraction <= 0.4 
Captopril
25-50mg 
three 
times 
daily 
6 
months 
 11%        4.7% 
ARR 6.3% in 
hospitalisation 
 
ARR = absolute risk reduction      P = placebo group   T = treatment group 
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3.  COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
This paper focuses on two questions: 
 
1.  Does the use of ACE Inhibitors in heart failure reduce the overall patient treatment 
 costs? 
 
2.  Are there financial savings to be made by switching from expensive ACE Inhibitors to 
 cheaper ones – whatever the indication for therapy? 
 
This section of the paper has been sub-divided into three main sub-sections. 
   
 The first sub-section reports the evidence found in the literature for cost-effectiveness of 
using ACE Inhibitors for patients with heart failure.  
 The second sub-section directly addresses question 1 and describes the results of 
modelling the costs and potential resource savings of treating those heart failure patients 
in a ‘typical’ English health district who are not currently on ACE Inhibitor therapy, but 
who would benefit from such treatment. Emphasis is on the cost-savings which would 
result from reduced in-patient hospitalisations.  
 The third sub-section addresses question 2 and identifies a number of resource 
implication scenarios from substituting more expensive ACE Inhibitor formulations with 
cheaper, but equally effective, ACE Inhibitors for conditions including heart failure and 
hypertension. 
 
 
3.1   Cost and Benefit Evidence from the Literature 
 
3.1.1 Introduction 
The studies conducted to assess the clinical effectiveness of ACE Inhibitors vary greatly in 
the characteristics of the patients studied in terms of: age, sex, symptoms of heart failure, 
duration and degree of heart failure, association with myocardial infarction, and in the end 
points of hospitalisation, death and progression to heart failure. Thus, the assessment of 
costs and potential savings of the management of heart failure is problematic. 
 
 10 
There have been a small number of economic analyses investigating the use of ACE 
Inhibitors for heart failure. These are summarised in this sub-section by looking at the total 
burden of illness, more general cost-effectiveness issues, and, given the focus of the 
question addressed in this section, giving some specific focus to the benefits from reduced 
hospitalisation. The SOLVD treatment trial
4
 has been used as the basis for nearly all 
published economic analyses because of the large numbers recruited into it. 
 
3.1.2 Burden of Illness 
In their paper of 1993, McMurray et al. produced a burden of illness model, which estimated 
the direct total cost of heart failure to the NHS to be in the region of £360m (1990/91 prices),   
that is, around 1% of the NHS budget.
15
  Some 60% of this figure was attributed to the direct 
costs of hospitalisation. This expenditure is expected to rise largely as a result of the ageing 
of the population. 
 
Results published in Bandolier
39
 (based on the work by McMurray et al.
15
) indicate the 
potential costs and benefits over a one year period to a health authority of 250,000 
residents. Cost estimates range from a net saving of £60,000 to a net cost of £76,000 
depending on a 2% or 40% day case initiation assumption respectively. Bandolier
39
 reports 
that around 40 deaths and 300 hospital admissions could be prevented each year through 
the appropriate use of ACE Inhibitors. 
 
3.1.3 General Cost-effectiveness 
Effectively, this paper already accepts that the case for the cost-effectiveness of ACE 
Inhibitors in the treatment of heart failure is proven. However, the reported evidence from 
published papers is summarised below.  
 
The cost-effectiveness of medical technologies is usually represented using a cost-
effectiveness ratio, such as, a cost per life year gained (LYG). However, if an intervention is 
found to produce net savings, it is not usual to present cost-effectiveness ratios because of 
the negative numerator.  
 
The CONSENSUS trial
22
 showed a 31% relative reduction in mortality at 12 months for heart 
failure patients treated with ACE Inhibitors. The mortality gains for those patients with 
progressive heart failure were more like 50%. In the larger SOLVD
4
 study (sample 2,569), 
patients with mild to moderate heart failure were followed-up over a four year period. Those 
 11 
randomised to the treatment group (2.5mg to 20mg enalapril) had a relative reduction in 
mortality risk of 16%  (95% CI of 5%-26%). The largest reduction was seen in the 
progressive heart failure population, that is, a 22% risk reduction (6%- 35%).
4 
 
Hart et al.
40
 investigated the cost-effectiveness of enalapril in the treatment of mild to 
moderate heart failure patients in the UK, using the results of the SOLVD study. The LYG, 
discounted at 6% over four years, was estimated at 0.137 per patient. The LYG figure may 
have been under-estimated given that 25% of the patients intended for treatment by placebo 
were being treated with enalapril by the end of the study. 
 
Hart’s simple one way sensitivity analysis showed direct NHS costs per life year saved 
varying from net savings of £200 per patient to a net cost of £3,100 per LYG (1990/91 
prices). The savings are primarily a result of reduced hospitalisations as discussed below. 
Hart’s more central estimate of cost per LYG is given as £251, although the results are very 
sensitive to whether initiation of treatment is in the primary or secondary sector. The SOLVD 
team recommended that 40% of heart failure patients required one day of in-patient 
initiation. The latter scenario was the baseline assumption used to derive the £251 per LYG 
estimate in the Hart paper
40
. In fact only 1.2% of patients in the trial required an in-patient 
admission to initiate treatment.
4
 Consequently, the already small costs per LYG in the 
‘central’ scenario are likely to be over-estimated. 
 
An Australian study
41 
again used the SOLVD treatment trial results to undertake an 
economic analysis.  Allowing for differences in methodologies, the results are broadly similar 
to those found by Hart et al. in the UK.
40
 
 
A Dutch study used Markovian modelling techniques to examine the 10 year effects of ACE 
Inhibitor treatment for congestive heart failure (CHF).
9,42
 Again, the analysis was based on 
the SOLVD trial and includes extrapolations of treatment effects beyond the four year trial 
period. The analysis showed net cost savings across a range of sensitivities and, as such, 
no cost-effectiveness ratios were calculated. These conclusions support the case for this 
paper to analyse savings rather than cost-effectiveness per se. 
 
3.1.4 Effects on Hospital Admissions 
Use of ACE Inhibitors in the treatment of heart failure secondary to LVD may improve 
symptoms, prolong life, prevent hospitalisation, and improve quality of life. Any treatment 
which improves symptoms can be expected to reduce hospitalisations and, therefore, 
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potentially save money. Given the relatively low cost of ACE Inhibitor treatment compared 
with hospitalisation, it is possible that this intervention has the potential to be a cost-saving 
or cost neutral option, and it is the effect on hospitalisations which is likely to be pivotal to 
any economic evaluation. 
 
Of the major ACE Inhibitor trials, seven have collated data on hospitalisation and these are 
listed in a recent publication.
43
 The SOLVD treatment trial probably has the most useful 
information about hospitalisation effects because of the larger sample size (2,569 patients), 
the broadly representative population characteristics, and the longer length of follow-up (22-
55 months, mean 41.4 months). The fact that the SOLVD trial excluded severe heart failure 
patients could mean that the potential effects of ACE Inhibitors are under-estimated using 
the results of this study. 
 
It is unfortunate, given the pivotal role of the hospitalisation effect, that the different studies 
report widely differing non-treatment hospitalisation rates, ‘relative’ risk reductions (RRR)
a
 
and absolute risk reductions (ARR)
b
 of hospitalisation following treatment with ACE 
Inhibitors. This is in part due to the trials being concerned with different patient groups. 
However, it is also due to the published papers not being explicit enough about the reported 
definition of hospitalisation. Specifically, some papers report the proportion of patients 
hospitalised, whereas others report the total number of hospitalisations. A significant 
proportion of heart failure patients have more than one episode of hospitalisation in a given 
period. This distinction is important in the context of the current paper, because Section 3.2 
is concerned with the effect of ACE Inhibitors on reducing demand for hospital resources in 
total. As such, this paper is more concerned with analysing the total reduction in 
hospitalisations and not simply the number of patients with reduced hospitalisations.  
 
To  illustrate the  point about the variations and confusion in reported hospitalisation effects 
in the published papers, the following all purport to be reporting the results from the SOLVD 
trial. Bandolier,
39
 for example, reports that the SOLVD trial indicates a 30% RRR for 
hospitalisations. Davie and McMurray
43
 also report a 30% RRR for hospitalisations from 22 
per 100 patient years down to 15.4 per 100 patient years in the SOLVD treatment group 
(ARR = 6.6 per 100 patient years). Hart,
40
 on the other hand, also reporting the results of the 
SOLVD trial, indicates that the RRR of hospitalisation from heart failure is 23.9% from 0.67 
                                                 
a
 RRR - The proportional reduction in rates of bad events between experimental and control 
participants in a trial, calculated as (Experimental Event Rate - Control Event Rate) / Control 
Event Rate. 
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hospitalisations per patient per year in the placebo group to 0.51 for the treatment group 
(ARR = 0.16 per patient per year). Our own analysis of the published SOLVD results show a 
RRR of hospitalisation from heart failure of 15.5% from 0.64 hospitalisations per patient per 
year in the placebo group to 0.54 for the treatment group (ARR = 0.10 per patient per year). 
The SOLVD investigators report that treating 1,000 patients with mild to moderate heart 
failure for three years with an ACE Inhibitor would prevent about 50 premature deaths and 
350 hospitalisations.
4
 The interpretation of the SOLVD hospitalisation analysis reported by 
Hart and the authors of this paper is thus in line with the analysis presented by SOLVD 
themselves. 
 
In the CONSENSUS 1 trial
22
 (sample size 253) patients with severe heart failure randomised 
to 2.5mg-40mg enalapril had significantly fewer hospital admissions and spent fewer days in 
hospital than the placebo group. That is, 7.3 admissions per 1,000 days at risk with 15% of 
study days in hospital, compared with 10.1 admissions per 1,000 days at risk with 19.6% of 
study days in hospital respectively.
21
 
 
3.1.5 Summary 
The discussion in Section 3.1 has demonstrated the significant resource burden of heart 
failure in the UK, that is, around 1% of the NHS budget with 60% of this being attributed to 
hospitalisation costs.  
 
Hospitalisation costs play a pivotal role in the economic analysis of ACE Inhibitors for heart 
failure therapy. The most useful source of hospitalisation information from the trial data is 
that provided by the SOLVD treatment trial. However, it is also one of the most 
misinterpreted pieces of information presented in subsequently published papers. This 
paper has noted the relevance of the hospitalisation effects of ACE Inhibitors reported by 
the SOLVD trial, and as subsequently interpreted by Hart and ourselves. 
 
Economic analyses from the UK and around the world have demonstrated the likelihood of 
cost savings from the treatment of heart failure patients with ACE Inhibitors. The main UK 
study by Hart et al.
40 
had a central scenario with a small cost per LYG but was based upon 
relatively pessimistic assumptions about the need for day case treatment initiation. The 
analysis published in Bandolier
39
 indicated how changing the initiation assumption changes 
the balance of resource usage from net costs to net savings. The body of evidence from the 
                                                                                                                                                        
 
b
 ARR - The absolute reduction in rates of bad events between experimental and control 
participants in a trial, calculated as (Experimental Event Rate - Control Event Rate) 
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literature is in favour of the likelihood of ACE Inhibitor therapy for heart failure resulting in 
net resource savings, supporting the relevance of question 1 posed in the current paper 
(see page 9). 
 
3.2 Modelling the Net Cost Effects of ACE Inhibitor Therapy in a ‘Typical’ District 
 
3.2.1 Methodology 
A simple spreadsheet model has been built to analyse the economic impact of the use of 
ACE Inhibitors in a standard English health district with a population of 500,000. The model 
has the following key variables: 
 
 Prevalence of congestive heart failure; 
 Proportion of congestive heart failure patients already on ACE Inhibitors; 
 Proportion of congestive heart failure patients not suitable for treatment with ACE 
Inhibitors; 
 ACE Inhibitor drug costs; 
 Echocardiography test costs; 
 Additional GP visits and U&E tests required; 
 Proportion of ACE Inhibitor patients initiated in hospital; 
 Existing hospitalisation rate per patient year; 
 Percentage reduction in hospitalisations from ACE Inhibitor use; 
 Average in-patient LOS; 
 Percentage reduction in LOS following the use of ACE Inhibitors; 
 Average cost per in-patient day. 
 
The following analysis requires a number of assumptions. A simple (non-age specific) 
prevalence rate for the whole population is assumed, and a proportion of these patients are 
assumed to be prescribed ACE Inhibitors already. Of the remaining population, a proportion 
will be assumed to be unsuitable for treatment with ACE Inhibitors, due to contraindications. 
These assumptions will identify a population of heart failure patients who are suitable for 
treatment with ACE Inhibitors, but who currently do not take the drug. In economists’ terms, 
this is the identified marginal population. 
 
The cost of treating these patients with ACE Inhibitors is estimated in the model by 
estimating the annual ACE Inhibitor drug treatment cost and making assumptions about the 
additional number of GP consultations required to undertake U&E tests. The latter are 
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usually undertaken before initial treatment with a low dosage ACE Inhibitor and every time 
the dosage is increased in the first months of treatment. Each patient to be considered for 
treatment with ACE Inhibitors is also assumed to require an echocardiogram to confirm the 
diagnosis of heart failure. The model requires an assumption about the proportion of heart 
failure patients who require hospitalisation for ACE Inhibitor initiation. 
 
Mainly because of inadequate data, the model assumes that cost savings result only from 
reduced demand for secondary sector in-patient hospitalisation. That is, any reduced 
demand for GP consultations, out-patient visits, non-ACE Inhibitor drug costs etc., is 
excluded, although it is acknowledged that such savings may not be insignificant. In this 
respect, the model will under-estimate the potential cost savings of ACE Inhibitor treatment 
for the given population.  
 
The model examines only the ‘year one’ costs and savings of ACE Inhibitor treatment. 
Reasons for restricting the analysis to ‘year one’ include the fact that most of the key source 
data are aggregated and, consequently, it was felt that a more detailed modelling exercise 
involving time estimates of treatment effects might be ‘over-working’ the available data. The 
costs of increasing the use of ACE Inhibitors are likely to be significantly higher in ‘year one’ 
compared with subsequent years because of the need to treat the existing stock of patients 
who could benefit from treatment. This is likely to have consequences in terms of the 
increased need for investment in drugs, echocardiography, and U&E testing for example. 
Subsequent years’ costs will be dependent largely on new demand for treatment, which will 
be determined by only the year on year incidence of heart failure. 
 
Also, ‘year one’ costs for items such as echocardiograms and other diagnostic tests should 
ideally be discounted over the increased survival time of treated patients.  The fact that they 
have not been means a further front loading of the costs into ‘year one’.  Consequently, the 
decision to base the model on the ‘year one’ costs and savings will bias the results towards 
higher costs of implementing the treatment policy. 
 
3.2.2 A Central Scenario 
Prevalence 
The range of prevalence for heart failure reported in this paper is from 0.1% to 3%, although 
this will be representative of a whole range of severities. The most commonly quoted 
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population prevalence is 1%
40
 and this figure will be used as the central assumption 
scenario for modelling.  
 17 
Already on ACE Inhibitors 
A number of the papers from the early 1990s suggested that somewhere in the region of 
10% of heart failure patients were already being treated with ACE Inhibitors. Recent work by 
North Derbyshire Health Authority indicates that that figure has risen to around 40% of its 
own heart failure population. Dr Joanne Carter of the Kiverton Park Medical Practice in 
Rotherham has indicated in personal correspondence that 36% of the practice’s own heart 
failure patients are already on ACE Inhibitors. This figure has been achieved without a 
concerted drive to achieve it and the practice feels that it can achieve a much higher 
proportion. The model’s central scenario assumes that 40% of heart failure patients are 
already being treated with ACE Inhibitors. 
 
Unsuitable for Treatment with ACE Inhibitors 
There is little published evidence about the proportion of heart failure patients unsuitable for 
treatment with ACE Inhibitors due to contraindications and side-effects. Mair et al.
44 
report 
that 13.5% of 266 heart failure patients are unsuitable for ACE Inhibitors. Our central 
scenario assumes 10% unsuitable. 
 
Potential Unmet Demand 
With a population of 500,000, the central scenario assumes, therefore, that a population of 
2,500 heart failure patients (i.e. 500,000 x 1% prevalence x 50% suitable but not currently 
treated) is eligible for treatment with ACE Inhibitors. This is, in effect, the marginal 
(incremental) population to be analysed. 
 
ACE Inhibitor Prescribing Cost 
One of the recommendations from this paper is that patients be initiated onto ACE Inhibitors 
using ramipril, as it is one of the cheaper ACE Inhibitors on the market. The central case 
scenario assumes that the average dosage prescribed will be 2.5mg. At a cost of 26.9p per 
2.5mg tablet, the drug cost per patient per annum is assumed to be £98.19. Therefore, the 
marginal drug cost of treating the assumed 2,500 new patients is estimated at  £245,475 per 
annum.  
 
Echocardiogram Costs 
The central scenario assumes that each potential new ACE Inhibitor prescribed patient will 
receive one echocardiogram to confirm a diagnosis of heart failure. North Derbyshire Health 
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Authority has indicated an estimated cost per echocardiogram of £40 per test. This figure is 
used in the central scenario modelling, giving a total marginal cost of £100,000.  
 
Initiation Costs 
The SOLVD trial recommended that 40% of potential ACE Inhibitor heart failure patients be 
initiated onto the drug as short-stay in-patients. At the conclusion of the trial, however, only 
1.2% of patients with mild to moderate heart failure had required initiation in hospital. As 
time has passed, it is now accepted that the vast majority of patients presenting to their GP 
with suspected heart failure can be initiated onto ACE Inhibitors in the primary care setting.  
The central scenario assumes that 2% of patients require initiation in hospital. These 
patients have been costed assuming a generic one day in-patient stay.
c
  The other  98% of 
patients are initiated by GPs at a cost per patient of £10.30.
d
  The resulting marginal cost of 
initiation for the population is estimated at £35,288. 
 
U&E Costs 
It is good clinical practice for a potential ACE Inhibitor patient to undergo a U&E test prior to 
starting treatment with ACE Inhibitors. This would be followed by another test within two 
weeks of treatment commencing. It is also common practice to start patients on a low dose, 
subsequently increasing the dose if, and when, necessary. Each increase in dosage should 
be accompanied by another U&E test. Each patient would also be expected to have a U&E 
test once a year. However, assuming that our marginal group of patients is currently on 
diuretics, and that diuretic patients are also expected to have an annual U&E test, the 
annual U&E test for the new ACE Inhibitor prescribed patients is not an additional expense 
and, therefore, should not be included as a marginal cost in our economic analysis. The 
central case scenario assumes that a new ACE Inhibitor patient has an additional three U&E 
tests in ‘year one’. These tests have been costed in the model by assuming one GP visit 
(again costed at £10.30 per consultation) and one laboratory test at £4.20 per test.
e
  The 
total marginal cost for U&E testing in the central case scenario in ‘year one’ amounts to 
£108,750.  As the need to change the dose after ‘year one’ is unlikely, the demand for U&E 
tests after ‘year one’ will be incidence led and, therefore, significantly less than in ‘year one’. 
 
                                                 
c
 Netten and Dennett.
56
 Cost per generic in-patient day (1997) = £195.19 inflated by 3%. 
d
 Netten and Dennett.
56
 Cost per GP consultation (1997) inflated by 3%. 
e
 £4.20 is the cost of a laboratory test for a GP fundholder quoted by Central Sheffield University 
Hospitals Trust Biochemistry Dept. 
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Total Marginal Cost of Central Case Assumptions 
Assuming that these costs account for all the additional costs of treatment with ACE 
Inhibitors, the gross cost of the central scenario is modelled at £489,513 in ‘year one’. 
 
Cost Savings 
The model assumes that the cost savings from treatment with ACE Inhibitors result only 
from reduced in-patient hospitalisations. Any potential savings from reduced out-patient 
visits and reduced demand for GP time are not considered, although it is acknowledged that 
they could be significant. 
 
Hart
40
 reports that the hospitalisation rate per patient per year for the control placebo group 
in the SOLVD study was 0.67 per patient per year. Our own estimate of the same figure 
using the results reported by SOLVD is 0.64. Hart reports the RRR of hospitalisation for the 
ACE Inhibitor treatment group from the SOLVD study to be 23.9%, that is, an implied 
hospitalisation rate of 0.51 per patient per annum for the ACE Inhibitor treatment group (an 
implied ARR of 0.16 per patient per year). Our own estimate of the treatment group 
hospitalisation rate using the results reported by SOLVD is  0.54 per person per annum, that 
is, a RRR of 15.5% (ARR = 0.10 per patient per year). The original SOLVD paper itself 
concludes that it would expect 1,000 mild to moderate heart failure patients treated with 
ACE Inhibitors for a period of three years to experience 300 fewer hospitalisations. 
Assuming a central case scenario of 0.65 hospitalisations per patient per year for the non-
treatment group, the conclusions reported in the SOLVD paper imply that the RRR for 
hospitalisations is about 18% (ARR = 0.12 per patient per year). These latter figures are 
used to form the central case scenario assumption for hospitalisation effects, and are a 
compromise between Hart’s and our own interpretations of the hospitalisation effects 
reported by SOLVD. 
 
Work undertaken in North Derbyshire indicates that the average LOS for heart failure 
patients is 12.15 days. In addition to ACE Inhibitor treatment reducing admission rates for 
heart failure patients, North Derbyshire has indicated that treatment is associated with a 5% 
shortening of average LOS. Using these hospitalisation risk reduction and LOS 
assumptions, the model estimates that 4,363 bed days would be saved per annum by 
treating 2,500 heart failure patients with ACE Inhibitors. Using a crude cost per in-patient 
day of £201
f
, this implies an estimated potential saving of £877,255 per annum. 
                                                 
f
 Netten and Dennett.
56
 Cost per generic in-patient day (1997) = £195.19 inflated by 3%. 
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Net Savings from Central Scenario 
The results of modelling the central scenario imply potential savings of £387,743. The input 
assumptions and the outputs for the central scenario are summarised in Table 2 below. 
 
 
Table 2 Summary of Central Scenario Assumptions and Model Outputs 
 
Variable  Central Scenario Assumptions 
and Outputs 
Prevalence  1% 
Proportion already on ACE Inhibitors  40% 
Proportion not suitable for ACE Inhibitors  10% 
UNMET DEMAND 2,500 Heart Failure Patients 
ACE Inhibitor cost per patient per annum  £98.19 
Echocardiograms per ACE Inhibitor patient  1 
Cost per Echocardiogram  £40 
Additional U&E tests per ACE Inhibitor 
patient 
 3 
U&E test cost (GP + Analysis)  £14.50 
Proportion initiated in hospital  2% 
Cost per hospital initiation  £201.05 
TOTAL MARGINAL COST  £489,513 
IP rate per patient per annum (no-treatment 
group) 
 0.65 
RRR of hospitalisation from ACE Inhibitors  18% 
ARR of hospitalisation from ACE Inhibitors 0.12 per patient per year 
Average LOS for heart failure  12.15 days 
Average LOS reduction from ACE Inhibitors  5% 
Cost per in-patient bed day  £201.05 
NET IN-PATIENT COST   - £877,255 
  
NET MARGINAL COST  - £387,743 
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The use of the word ‘potential’ is deliberate, in that it indicates not only uncertainty around 
the central scenario, but draws attention to the fact that the in-patient savings will not 
automatically translate to financial savings to the commissioners of health care. Having said 
this, the bed day savings should not be dismissed. With a 90% occupancy assumption, the 
bed day savings amount to 13.3 beds (about half of an average sized ward’s bed allocation). 
 
Premature Deaths Prevented 
On the basis of 50 premature deaths prevented for every 1,000 patients treated for three 
years,
4
 and assuming that this converts to 16.67 deaths prevented per 1,000 patients 
treated per annum, treatment of the 2,500 central case patients would prevent 42 premature 
deaths per annum. 
 
3.2.3 Sensitivity analysis 
The effects on net marginal savings can be modelled by changing the assumed values of 
key input variables used in the central scenario. The sensitivity to demand is investigated 
using simple single variable sensitivity analysis. The cost and saving variable sensitivities 
are examined by investigating by how much the input assumptions need to change in order 
to eliminate the potential net savings which result from the central scenario assumptions. 
 
Demand 
The relationship between prevalence and net savings is a proportional one. That is, 
changing the prevalence assumption by x% increases the resulting net savings by x%. For 
example, doubling the prevalence from 1% to 2% doubles the net savings from £388,000  to 
£776,000.  
 
Varying the assumed 40% of heart failure patients already on ACE Inhibitors from 20% to 
60% changes the modelled net savings from £543,000 to £233,000 respectively. Thus, for 
every absolute 10% increase in this input assumption, there is a corresponding reduction in 
net savings of around £80,000, and vice versa. The latter is also true for any changes in the 
assumed value for the proportion of heart failure patients not suitable for ACE Inhibitor 
therapy. 
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Costs and Savings 
Simple one-way sensitivity analysis can be used to illustrate by how much individual variable 
assumptions need to change in order to eliminate the net savings modelled in the central 
scenario. The results of the analysis are presented in Table 3. 
 
Table 3 Required Changes in Individual Input Assumptions in the Central 
  Scenario in Order to Eliminate Modelled Potential Savings 
 
Input Variable Central Scenario 
Assumption 
Sensitivity 
Assumption 
Relative Percentage 
Change Required 
ACE Inhibitor drug cost 
per patient per annum 
 £98.19  £235.29  +240% 
Echocardiograms per 
patient 
 1  4.9  +490% 
Cost per Echocardiogram    £40  £195  +488% 
U&E tests per patient  3  13.7  +457% 
Initiated in hospital  2%  83.3%  +4,165% 
Non-treatment 
hospitalisation rate 
 65%  36%  -45% 
RRR of hospitalisation  18%  7.7%  -57% 
ARR of hospitalisation  0.12  0.05  -57% 
Cost per in-patient day  £201  £111  -45% 
 
The analysis shows, for example, that in order to eliminate the potential net savings of the 
central scenario, the assumed ACE Inhibitor drug costs per patient per annum would have 
to increase by 240% from £98 to £235. Likewise, the cost per echocardiogram would need 
to rise by almost 500% from £40 to £195 before the net cost saving result is eliminated. 
 
The hospitalisation assumptions are pivotal to the analysis, and represent the area of most 
uncertainty and confusion in the literature. The sensitivity analysis indicates that the 
hospitalisation assumption for the untreated patients would have to be reduced from 0.65 
per patient per annum in the central case to 0.36. The latter is very low compared with the 
figure reported in the SOLVD trial, although the trial was concerned only with patients who 
had mild to moderate heart failure. The implications for the number of hospitalisations 
avoided, is that it would be about one third of the reduction reported by SOLVD. 
 
Likewise, the central scenario assumption for the hospitalisation RRR following treatment 
with ACE Inhibitors would need to be lowered from 18% to 7.7%, the ARR being lowered 
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from 0.12 to 0.05 per patient per annum. Again the implication is that the hospitalisations 
saved would need to be less than a third of those reported by SOLVD.  
   
In summary, the sensitivity analysis indicates that the assumptions of the central case 
scenario would have to change substantially in order to eliminate the net saving result of the 
central scenario. The question is almost certainly “how big are the potential savings?” rather 
than “will there be any?” 
 
3.2.4 Discussion and Conclusions 
In summary, modelling has indicated that managing heart failure patients according to good 
clinical practice, that is, using echocardiographic investigation and treatment using ACE 
Inhibitors can be achieved with potential marginal cost savings. The central case scenario 
implies that, for a population of 500,000, an additional 42 premature deaths could be 
prevented per annum with a potential net cost saving of around £388,000 in ‘year one’. This 
modelling is based explicitly on a number of simplifying assumptions. Net savings may be 
greater or smaller than those modelled in the central scenario for a number of reasons.  
 
The exclusion of potential savings from reduced demand for out-patient and GP 
attendances through the use of ACE Inhibitors clearly implies that the modelled savings are 
under-estimated in the central case.  
 
Also, the demand and costs for U&E tests and echocardiography have been ‘front loaded’ 
into ‘year one’, which means that the actual net costs could be even lower than those 
indicated by the results of the modelled central scenario. For example, LVD is difficult to 
identify solely on the basis of signs and symptoms. The costs of echocardiography to 
improve and confirm diagnosis have been modelled by assuming one test per new ACE 
Inhibitor patient, to allow for the fact that echocardiograms are required once per patient 
before the initiation of treatment. The model indicates that the demand for echocardiograms 
in ‘year one’ is estimated to cost £100,000 (£40 x 2,500 patients). Thereafter, the cost of 
echocardiograms will be restricted to potential new incidence of heart failure patients. 
Assuming an incidence rate for heart failure of between 0.15% and 0.3%, the annual cost of 
echocardiography for heart failure after ‘year one’ is estimated at between £27,000 and 
£54,000 per annum.  
 
In addition, it would have been quite legitimate to have constructed the model so that the 
estimated marginal cost of £100,000 for echocardiography was annualised over the 
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expected lifetime of the patients. Assuming a 5% discount rate and a survival period of five 
years, for example, implies a repayment annuity of £23,097 per annum. This figure is 
significantly lower than our £100,000 ‘year one’ costing assumption.  
 
The increased use of echocardiography could result in potential savings from the reduction 
or avoidance of inappropriate or over-prescribing of diuretics and ACE Inhibitors for mis-
diagnosed patients. The Francis study,
45
 for example, demonstrated that 45% of diuretic 
patients had inappropriate treatment withdrawn following investigation by echocardiogram. 
These potential cost savings have not been modelled in this paper. A follow-up paper from 
the Edinburgh team has subsequently recommended screening out the need for 
echocardiography with pre-tests using electrocardiography.
46
  This option could result in a 
more cost-effective use of resources by reducing the demand for echocardiography by as 
much as 50%. Also, there are a number of new initiatives underway concerned with 
screening for, and the diagnosis of, heart failure. These involve the detection of peptide 
hormones in the blood, which have raised levels when the heart begins to fail. The potential 
implications for echocardiography of such initiatives will need to be monitored. 
 
The model does not allow for the possibility of induced extra demand for echocardiography 
for patients subsequently confirmed not to have heart failure. This induced demand will 
mean increased costs of echocardiography per heart failure patient detected. A recent study 
in Scotland showed inappropriate referral rates for open access echocardiography to be as 
low as 12%.
45
  Such a figure is well within the sensitivity range for the ‘echocardiograms per 
patient’ variable as demonstrated in Table 3. 
 
Because of the relatively high level of aggregation of the source data, modelling has been 
deliberately kept simple. The analysis has been confined to the ‘year one’ costs and benefits 
of treating heart failure patients with ACE Inhibitors. The model does not fully address 
issues associated with treatment over the lifetime of the patient. As such, the model does 
not account for changes in the reduction in risk of hospitalisation over time, nor does it 
account for the costs of treating patients who live longer because of their improved health 
state. Work already reported in this paper, which does model the life-time effects of ACE 
Inhibitor treatment, indicates that the cost-effectiveness of ACE Inhibitors, in terms of 
discounted LYG, is very favourable.  Life years may even be gained with cost savings. The 
sensitivity analysis presented in this paper also indicates that there are wide margins for 
error in the assumed values for the input variables of the model before the resulting 
potential savings are eliminated. 
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The analysis does not address the issue of potential resource implications from increased 
incidence of renal failure in the elderly resulting from combination therapy of ACE Inhibitors 
with Non-Steroidal Anti-inflammatory Drugs (NSAIDS). The latter needs to be monitored 
carefully because such effects could have considerable resource consequences. Also, there 
is a possible theoretical risk for patients with unilateral renal artery stenosis which will 
require longer-term monitoring, and may mean that screening for this condition is a wise 
precaution for patients at high risk.
46
  The latter group includes hypertensive patients over 
50 years of age and those with peripheral vascular disease, diabetes, or coronary artery 
disease.  
 
The SOLVD study excluded frail elderly patients and patients with severe heart failure. If the 
hospitalisation gains from treatment with ACE Inhibitors are lower for these groups of 
patients than those found in the SOLVD sample, then the hospitalisation savings indicated 
by our modelling will have been over-estimated. 
 
It is important to point out that the modelled bed day savings, whilst clearly a true 
opportunity cost saving, will not automatically accrue to the purchasers as cash savings, 
unless they can be incorporated into contracting. The benefits are more likely to manifest 
themselves in the form of reduced waiting times and increased bed capacity in wards no 
longer occupied by heart failure patients. Having said this, the marginal implications could 
be significant if a large Trust is looking to reduce demand for 13 beds in order to be able to 
close a ward. Alternatively, reduced demand for 13 beds could prevent, or at least delay, the 
need to build a new ward and, thus, avoid all the associated capital and other marginal 
costs. Any actual release of hospital resources would need to be managed locally. 
 
The implementation of a policy of wider treatment of ACE Inhibitors and the increased use 
of echocardiography (with or without other diagnostic tests) needs to be thought through 
and managed. Information and training may need to be given to GPs, and will inevitably 
require additional resources. Appendix 2 outlines how such a planned approach might be 
created using the lessons learned by the FACTS project team following the implementation 
of a policy to prescribe aspirin to patients at high risk of heart attack and stroke. FACTS (in 
personal correspondence) have indicated that the costs of implementing policies such as 
the aspirin policy are unlikely to be more than £100,000 in a ‘typical’ district. Such costs 
would need to be made available up front, but still imply a potential net savings result even 
in ‘year one’. 
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The main issues surrounding the increased use of echocardiography include:- 
 
 open access versus a consultant led service; 
 use of pre-testing using x-rays and electrocardiograms. 
 
Increased demand for these diagnostic services may mean that pump-priming monies need 
to be made available in those districts where the marginal change in demand requires 
capital investment.  
 
In summary, modelling has demonstrated that managing heart failure patients appropriately 
using diagnostic echocardiography and treatment with ACE Inhibitors is not only beneficial in 
health terms, but is likely to be achieved with a potential net resource saving. These costs 
and savings will fall unequally on the primary and secondary care sector, and the savings 
are essentially potential in cash terms to the purchaser. The recent White Paper’s
48
 
proposals to hand over unified budgets to Primary Care Groups (PCGs) will mean that the 
primary versus secondary balance of financial gains and burdens will be less of an issue 
than is the case under existing financial arrangements. A number of variables have not been 
included in the model which, on balance, is likely to mean even greater potential savings. 
The case for implementing a policy of wider treatment with ACE Inhibitors appears very 
strong, although its implementation will require careful planning, management, and possibly, 
some pump-priming monies. 
 
3.3 Are there Financial Savings to be Made by Switching from Expensive ACE 
Inhibitors to Cheaper Ones – Whatever the Indication for Therapy? 
 
ACE Inhibitors are generally expensive, costing from £60 to £240 per year of treatment 
depending on the drug and the dose. The Angiotensin II drugs range from £180 to £240 per 
year and are, therefore, generally more expensive than the first generation ACE 
Inhibitors.
49,50
 The Drug and Therapeutics Bulletin
49
 recommended prescribing the original 
three, captopril, enalapril and lisinopril, as there appeared to be little to choose between 
these and the multiplicity of newer products. Currently, however, ramipril is reportedly 
cheaper for a year’s course of treatment - between £72 and £115.
50
 It is thought, therefore, 
that switching patients to ramipril will result in considerable savings. 
 
There is evidence that the benefits from ACE Inhibitors are due to a class effect and not 
related to specific preparations.
51,52 
 Studies have also been performed to show that it is safe 
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to convert from one preparation to another.
53,54
 Therefore, if there are economic grounds for 
recommending that patients be changed to ramipril, there is evidence to support the clinical 
safety of such a policy. 
 
To test the hypothesis that there are savings to be made by changing people from their 
current ACE Inhibitor to ramipril, certain information is required: 
 
1. The number of people taking an ACE Inhibitor. 
2. The number of people who should be taking ACE Inhibitors – particularly in respect of 
heart failure. 
3. Which drug is being taken and for what clinical indication. 
4. What dose of the drug is being taken. 
5. What the recommended doses are for each clinical indication. 
6. What the equivalent dose of ramipril would be for each patient. 
7. The cost of each drug at whatever dose is used. 
 
However, the only piece of information known for certain is item 7. 
 
For most GP practices, information on items 1, 3, and 4 is either readily available on 
computer or could be discovered by searching patient records or by a combination of the 
two. However, at a health authority level this information is not available unless a deliberate 
attempt, as in North Derbyshire, has been made to ask practices to provide it. Even so, the 
number of patients who may be receiving inadequate doses of ACE Inhibitors is unknown. 
Such patients may need to increase their dose and, hence, this may increase the cost of 
ACE Inhibitor prescribing. However, this may be off-set by a number of patients currently 
prescribed an ACE Inhibitor, who may not require this particular type of drug if their 
diagnosis of heart failure is wrong and, hence, may be able to stop taking ACE Inhibitors. 
 
Although there are recommendations from the drug companies concerning therapeutic 
dosage, generally speaking this is supplied as a range with a starting dose and a maximum 
level. There are recommended dosages based on those used in the main trials. There may 
be marked differences between the dosage patients take of the same drug for the same 
indication. 
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Item 5 is probably not definable. Although the number of patients with heart failure can be 
estimated, an attempt to identify the number of patients with hypertension and in whom ACE 
Inhibitors would also be indicated, would be much less reliable. Issue 6 also remains 
unresolved. 
 
Analysis of PACT Data  
Prescribing Analysis and Cost (PACT) data supplied by the Prescription Pricing Authority  
are provided both at district and practice levels, in varying degrees of detail. At district level, 
it indicates the number of items (prescriptions) for a particular drug, which strength was 
prescribed, and the number of tablets prescribed. The cost is then calculated. However, 
problems include: 
 The number of patients receiving prescriptions cannot be calculated reliably. (Doctors 
may prescribe different quantities of tablets and different numbers of prescriptions for 
patients taking the same drug, at the same dose and for the same reason). 
 ACE Inhibitors are prescribed for hypertension, incipient heart failure (as occurs after an 
acute myocardial infarction), as well as CHF, and it is not possible to identify how many 
prescriptions are for which indication. 
 The therapeutic dose for the same drug may differ for each of these indications.  
 The cost of the drug, per milligram, varies according to strength i.e. the cost of a low 
strength tablet is relatively more expensive than a stronger tablet, but the actual cost of 
the stronger preparation will be greater. Thus, the therapeutic dose of a preparation is 
crucial to assessing its cost-effectiveness. 
The steps in the analytical process were as follows: 
 PACT data for Sheffield GPs for the quarter July to September 1997 were obtained. The 
total prescribing population for Sheffield GPs is 543,000. 
 The defined daily dose (DDD) based on the World Health Organisation (WHO)
55 
recommendations (see Table 4),
 
was used to calculate the
 
total number of DDDs for 
ACE Inhibitor prescribing in Sheffield. For example, the DDD of captopril is 50mg daily. 
Therefore, 50mg are 1 DDD and 25mg is 0.5 DDD. ACE Inhibitor/diuretic drug 
combinations were excluded. 
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 The total prescribing cost for Sheffield GPs for ACE Inhibitors was calculated. The 
second generation ACE Inhibitors were totalled separately as there are no 
recommendations concerning DDDs for these drugs. 
 The current costs of the ACE Inhibitors most commonly prescribed are shown in  
Table 5. 
 All the calculations relate to one quarter only, unless otherwise stated. 
 
NB: There may be aspects of Sheffield’s prescribing profile which are not typical of other 
areas and, therefore, the results of this analysis should be considered with this in 
mind. 
 
 
Table 4 Defined Daily Doses of ACE Inhibitors55 
  
ACE Inhibitor DDD mg 
Benazepril  7.5 
Captopril  50.0 
Cilazapril  2.5 
Delapril  30.0 
Enalapril  10.0 
Fosinopril  15.0 
Lisinopril  10.0 
Moexipril  15.0 
Perindopril  4.0 
Quinapril  15.0 
Ramipril  2.5 
Spirapril,  6.0 
Trandolapril   2.0 
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Table 5 Current Cost of 28 Days’ Treatment of the Four ACE Inhibitors 
Most Commonly Prescribed50 
 
ACE Inhibitor Cost of 28 days’ treatment 
(£) 
Ramipril  1.25mg  5.30 
Captopril 12.5mg bd (twice daily)  5.79 
Captopril 25mg bd  6.93 
Ramipril  2.5mg  7.51 
Lisinopril 2.5mg  7.64 
Enalapril 5mg  7.86 
Captopril 50mg bd  9.34 
Ramipril  5mg  9.55 
Enalapril 10mg  11.03 
Lisinopril 10mg  11.83 
Enalapril 20mg  13.10 
Lisinopril 20mg  13.38 
Ramipril  10mg  19.10 
Enalapril 40mg  26.20 
Lisinopril 40mg  26.76 
 
The analysis is based on the residual data after excluding the information for patients 
already on captopril, ramipril, and the second generation ACE Inhibitors. The reasons for 
this are: 
1. Captopril is given two or three times daily. Changing to a once daily dosage of ramipril 
may not be straightforward. Also generic captopril is cheaper than ramipril. Therefore, 
there is no saving to be made by changing these patients to ramipril. Those taking a 
proprietary brand of captopril should probably be encouraged to change to the generic 
variety.  
2. Those patients already on ramipril will not be changed and, therefore, there are no 
savings to be made from these patients. 
3. There is no DDD for the second generation ACE Inhibitors. Although they are more 
expensive, they represent only a small proportion of ACE Inhibitor prescribing at the 
moment, and so would contribute little to any overall potential savings. 
 
Table 6 shows the summary of the PACT data for Sheffield GP prescribing for the quarter 
July to September 1997. It also shows the number of DDDs available for exchange and the 
total cost from which savings might be made. 
 
The total number of DDDs available for exchange is: 921,664. 
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The total cost of ACE Inhibitor prescribing, from which savings might be realised is: 
£341,046 
 
Table 6 Summary of PACT Prescribing Data for Sheffield GPs: July to 
September 1997 
 
 Drug   Cost  
(£) 
Total no. 
DDDs 
 Captopril    73,065  228,755 
 Cilazapril    6,162  19,196 
 Enalapril    175,453  528,486 
 Fosinopril     14,740  28,316 
 Lisinopril    129,654  308,572 
 Losartan    19,438  30,201 
 Perindopril     6,973  14,466 
 Quinapril      4,564  16,138 
 Ramipril    26,774  134,838 
 Trandolapril    3,497  6,488 
 Valsartan    493  952 
      
TOTAL 1:     460,818 1,316,410 
TOTAL 2:  total excluding ACE Inhibitor second 
generation 
 440,886 1,285,257 
TOTAL 3:  total 2 excluding ramipril    414,112 1,150,419 
TOTAL 4:  total 2 excluding captopril    367,821 1,056,502 
TOTAL 5:  total 2 excluding ramipril  and captopril    341,046  921,664 
 
 
The following paragraphs discuss a number of possible scenarios for changing the current 
profile of ACE Inhibitor prescribing to the use of ramipril. A number of caveats and 
explanations for the different scenarios are highlighted. The results are shown in Table 7 
and the calculations behind them are set out in Appendix 3. 
 
 
Scenario 1:  If the 921,664 DDDs were to be directly replaced by ramipril 2.5mg – low 
maintenance regime: 
 
Potential savings are £667,406 per annum for a population of just over 543,000 with a 
similar CHD profile i.e. savings of 37.8 % of ACE Inhibitor budget. 
 
1. This total saving is unlikely as some patients will not wish to change and others will not 
be satisfied by a change even if they agree to it initially. 
2. A proportion of patients will require 5mg or even 10mg daily which will increase the cost. 
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3. This figure may be increased because of patients on lower doses, but decreased by 
patients on higher doses. 
 
Scenario 2:  If the 921,664 DDDs were to be replaced by ramipril 5mg – high  
 maintenance regime: 
 
Potential savings are £107,034 per annum for a population of just over 543,000 with a 
similar CHD profile i.e. savings of  6% of ACE Inhibitor budget. 
 
Thus, the potential savings by this methodology are likely to be somewhere in between 
scenarios 1 and 2.  
 
However, analysis of the Sheffield PACT data shows that 75% of prescribing is for the 5mg 
preparation (see below). This suggests that the average dose of ramipril is not 2.5mg but 
5mg once or even twice daily. The Prescribing Support Unit in Leeds, by calculating the 
average daily dose (ADD) for ACE Inhibitors, confirms this. For all ACE Inhibitor 
preparations, the ADD is the same as the DDD, as defined by the WHO, except for ramipril. 
The ADD for ramipril is 5mg and not 2.5mg. Thus, the potential savings are likely to be 
nearer those of scenario 2.  
 
Scenario 3:  If the 921,664 DDDs were to be replaced in the same proportions as 
 ramipril is currently prescribed in this population, i.e. 
 
3.1% for 1.25mg preparation 
21.8% for 2.5mg preparation 
75.1% for 5mg preparation 
 
Potential savings are £181,280 per annum for a population of just over 543,000 with a 
similar CHD profile i.e. savings of 10% of ACE Inhibitor budget. 
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Scenario 4: If the 921,664 DDDs were to be replaced in the same proportions as ramipril 
is currently prescribed in this population, allowing for 25% of prescriptions 
being for 10mg daily: 
 
From PACT data it is not possible to determine the proportions of prescriptions for 5mg 
once and 5mg twice daily. However, looking at the prescriptions for multiples of two months 
supply of 5mg tablets (using 2 months supply of 5mg daily as a proxy for one month of 5mg 
twice daily) suggests that there is approximately a 
2
/3 – 
1
/3 split. As 75% of ramipril 
prescriptions are for the 5mg preparation, this suggests that 25% of all ramipril  prescribing 
is for 5mg twice daily. This 25% accounts for 50% of the cost of ramipril prescribing as the 
cost is twice that of 5mg daily. 
 
Thus, the cost of ramipril, allowing for 25% of prescriptions  for 10mg = £373,983. 
 
This is greater than the current prescribing costs of £341,046 and, therefore, represents a 
potential extra cost. 
 
 
Table 7 Summary of Scenarios 1 - 4 
 
Scenario: with Total Available 
DDDs Replaced by: 
Costs 
(£) 
Potential Savings 
per annum (£) 
Scenario 1: ramipril 2.5mg  174,194  667,406 
 
Scenario 2: ramipril 5mg 
 
 314,287 
 
 107,034 
 
Scenario 3: ramipril in proportions 
of doses currently prescribed 
 
 
 295,726 
 
 
 181,280 
 
Scenario 4: ramipril in proportions 
of doses currently prescribed, 
allowing for 25% @ 10mg daily 
 
 
 
 373,983 
 
 
 
 - 32,937 
 
Caveats 
   
1. Savings are dependent on:  
 
 which DDD of ramipril is used; 
 what the proportions of prescribing would be for the different doses of ramipril; 
 which strengths of ramipril are used. 
 
2. There will be a cost for changing patients from their current ACE Inhibitor to ramipril.  
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Estimating the number of patients on ACE Inhibitors by dividing the number of DDDs by 365 
days gives an estimate of 2,525 patients. Assuming an extra four visits to the GP to 
establish the change and clinical stability, at a cost per visit of £10,
56
 the cost of changing 
these patients is 2,525 x 4 x £10 = £101,000 (for the other ACE Inhibitors 30% of 
prescriptions are for DDD, 42% for >DDD, 27% for < DDD). 
 
Potentially, this eliminates the potential savings for scenarios 2 and 3 in the year of change. 
It must be remembered that patients will generally be on ACE Inhibitors for life, once 
established, and, therefore, the savings identified might be expected to accrue after the first 
year. The mortality remains high, even for patients on ACE Inhibitors and, therefore, the 
benefits gained by a mass change-over exercise may be less than the scenarios imply. 
However, initiating treatment using less expensive preparations will reduce significantly the 
prescribing costs for heart failure patients.  
 
The prescribing profiles of the other ACE Inhibitors may be different from that of ramipril. 
There may be a larger percentage of patients on the smaller doses. Patients currently on 
ramipril may be prescribed it predominantly for heart failure and this may account for the 
25% taking the higher doses. The AIRE
26
 study used a dose of 5mg twice daily. If the 
proportion of other ACE Inhibitors is predominantly for hypertension then changing these 
patients to ramipril might increase the proportions on doses of less than 5mg daily. This 
would increase the savings. 
 
3.3.1 Discussion and Conclusions 
It would appear from the foregoing analysis that, at a dose of 5mg daily or less, ramipril  is 
currently cheaper than other ACE Inhibitor preparations (except generic captopril). However, 
if the number of patients who require 5mg twice daily, is as high as 25%, this changes the 
pricing profile considerably, to the extent that directly changing patients to ramipril would 
certainly not save money and may be more expensive. Thus, the number of patients 
requiring more than 5mg daily, may be sufficient to change the balance of cost-
effectiveness away from a recommendation to convert all patients to ramipril .  
 
If the caveat is accepted that all patients requiring more than 5mg daily revert back to their 
original preparation then there are still savings to be made. This then has to be weighed 
against the cost of seeing patients several times to establish a change, monitoring the 
effects and counselling, changing about a quarter back again and so on. These costs are 
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likely to counter balance the potential savings in the first year. For individual practices and 
doctors these costs may be ‘absorbed’ in routine work and, therefore, only the savings in the 
drug budget may be apparent, rather than the lost opportunity costs in seeing ‘extra’ 
patients. However, year on year after the first year, the potential savings will probably 
outweigh the costs of changing patients to ramipril.  
 
Currently, it would seem sensible to recommend starting new patients on ramipril, as about 
75% of these will be on the lower dose. Those patients requiring 10mg of ramipril could then 
be changed to another ACE Inhibitor.  
 
If changing patients to ramipril  is to be advocated, clear protocols and methodologies will be 
required. Also, product developments, such as, the introduction of new drugs or the removal 
of patent from competing brands, such as, enalapril, will mean that the cost-effectiveness of 
any advocated policy will need to be reviewed constantly. For example, enalapril is currently 
the major ACE Inhibitor prescribed in Sheffield. Given that enalapril will soon become 
available generically, thus lowering its price, a policy to switch current ACE Inhibitor patients 
in Sheffield from enalapril to ramipril  may not be seen as sensible at this point in time. 
 
The foregoing analysis is based on Sheffield data, which may not be representative of other 
districts. Other districts may wish to undertake their own local analysis of PACT data and 
should be aware that the above conclusions drawn may not be relevant to their own locality. 
 
The cost-effectiveness of Angiotensin II drugs is not yet established. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
4.1 More Extensive Use of ACE Inhibitors 
 
The following options are not necessarily alternatives to one another. Options 1 to 3 can be 
taken in any combination. 
 
1. Increase the use of ACE Inhibitors for non-contraindicated heart failure patients. The 
experience of the Sheffield FACTS project and/or the North Derbyshire PACE project 
can be used as models for implementing the policy. The comments about the class 
effects of ACE Inhibitors and the implications for appropriate low cost prescribing in 
section 3.3 of this paper should be noted when developing policy.  
 
2. Enhance echocardiography services to improve the diagnosis of heart failure leading to 
more appropriate prescribing of ACE Inhibitors and diuretics. This option may require 
pump-priming monies. 
 
3. Supplement echocardiography services with pre-diagnostic tests for heart failure using 
chest x-ray and electrocardiograms. This pre-screening option may encourage more 
appropriate use of echocardiography. Again, pump-priming monies may be required in 
some districts. 
 
4. Healthcare commissioners and providers need to decide whether echocardiography, x-
ray, and electrocardiography are to be provided using an ‘open access’ or a 
consultancy-led model.  
 
5. Maintain the status quo with all its apparent implications for inefficient use of hospital 
and pharmaceutical resources and loss of health gain for the population. 
 
4.2 Substituting More Expensive for Lower Cost ACE Inhibitors 
 
The following options are not necessarily mutually exclusive. 
 
1. Allow current clinical practice to direct the prescribing of ACE Inhibitors in terms of both 
the patients who receive them and which drugs are prescribed. 
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2. Advocate that new patients requiring an ACE Inhibitor should currently be initiated on 
ramipril but, if the therapeutic dose required exceeds 5mg daily, they should be changed 
to a different preparation. (Enalapril will shortly come off patent so that its generic price 
could become similar to that of ramipril.) 
 
3. Advocate changing patients who are on the DDD of their ACE Inhibitor (excluding 
captopril and ACE Inhibitor II) to 2.5 mg of ramipril. 
 
4. Advocate changing all patients to ramipril 1.25 mg and increasing the dose as 
necessary, but anyone requiring more than 5 mg daily should be changed back to their 
previous preparation. (Assume that patients in severe heart failure are likely to require 
the higher dose of ramipril and, therefore, should not be changed.) 
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APPENDIX 1: North Derbyshire Health Authority - Promoting Action on Clinical 
Effectiveness Project (PACE) 
 
Objectives 
 To improve the investigation and management of patients with congestive cardiac failure 
in North Derbyshire. 
 
 To develop open access provision of echocardiographic resources. 
 
 To promote effective prescribing by increasing the prescription of ACE Inhibitors and 
decreasing the unnecessary prescription of loop diuretics. 
 
 To encourage audit in order to monitor progress. 
 
The PACE Project has employed a variety of change techniques in order to encourage the 
use of echocardiography and the subsequent prescribing of ACE Inhibitors where 
appropriate, including distributing practice information packs, audit and re-audit of the 
records of patients with heart failure, an education programme, and the development of 
open-access echocardiography services in local Trusts. 
 
Practice Information Pack 
An information pack was compiled and distributed to all the practices in North Derbyshire 
early in the project. This followed the format of the FACTS practice information packs on 
aspirin. 
 
The pack contained information on the PACE project, the research evidence on the 
management of heart failure, details of the audit methodology, the prescribing of ACE 
Inhibitors and a cost benefit analysis on the management of heart failure patients in addition 
to epidemiological data and details of available open access echocardiography services. 
 
Audit 
Following a pilot study involving three GP practices, an initial audit of the records of a 
sample of patients diagnosed as having heart failure was undertaken involving 48 (78%) of 
the practices in North Derbyshire and covering 86.5% of the population. 
 
A re-audit of a random sample of records of patients diagnosed as having heart failure has 
been undertaken between 15 and 24 months after the first audit, involving 49 (80%) of the 
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existing 61 practices, in order to establish change in clinical practice over the period of the 
project. Forty three practices took part in both audits. 
 
The audit criteria were: 
 
 All patients with suspected heart failure should have had an echocardiograph. 
 
 All patients with proven heart failure and without contraindications should be on an ACE 
Inhibitor. 
 
 All patients on ACE Inhibitors should have their U&E checked before starting and again 
within two weeks of starting an ACE Inhibitor. 
 
The re-audit results show a 2% increase overall in the use of echocardiography in the 
diagnosis of heart failure. Although this is not a huge increase, given that the open access 
service at Chesterfield and North Derbyshire Royal Hospital only started in November 1997 
it demonstrates the right trend. The  numbers of patients referred to the service by each 
practice showed a large variation, with eight practices referring nearly half of those scanned, 
and 30% of the practices not making any referrals at all. 
 
Overall 49% of the total sample of patients were taking ACE Inhibitors, an improvement of 
4% on the initial audit. Studies have shown that the average proportion elsewhere is only 
around 30-35%, which indicates that a relatively high proportion of heart failure patients are 
treated appropriately in North Derbyshire. 
 
Disappointingly, the audit shows that only 49% of the patients had their U&E checked before 
starting ACE Inhibitors (a decrease of 5% from the initial audit) and only 35% of patients 
have had their U&E checked within six weeks of starting ACE Inhibitors, (a decrease of 4% 
from the first audit). This issue will be addressed in the next series of education meetings 
and practice visits. 
 
The re-audit results also show that frusemide prescribing has risen from 56% to 63% of the 
total and co-amilofruse has dropped significantly from 19% to only 11%. 
 
Education programme 
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A series of formal educational meetings were held during 1997 for the GPs in each locality. 
The content of the meetings centred around information about the PACE Project, 
echocardiography as a diagnostic tool, and the results of the initial audit. The meetings were 
well attended involving 51 GPs from 32 (52%) of the 61 practices. 
 
A second series of meetings is being held during 1998 when the focus will be on the use of 
open-access echocardiography services, including results on the analysis of the first few 
months of open-access services, the results of the re-audit and the management of those 
patients in whom the diagnosis of heart failure is not confirmed by echocardiography, but 
who present with similar symptoms. 
 
A practice nurse study day has also been held in order to inform and involve the nurses of 
the project work and to explore with them how other members of the practice team can be 
involved in promoting change on the basis of evidence. 
 
The development of open access echocardiography services 
Open access echocardiography services have been developing in provider Trusts 
increasingly over the past 2-3 years. 
 
North Derbyshire Health Authority, through the PACE project, has recently commissioned 
open access echocardiography services at Chesterfield and North Derbyshire Royal 
Hospital and has worked with other NHS Trusts in the development of echocardiography 
services (Stepping Hill, Stockport; East Cheshire and Northern General Hospital, Sheffield). 
 
Following the success of an initial small pilot study, a larger pilot service was set up at 
Chesterfield and North Derbyshire Royal Hospital (CNDRH) enabling 52 GP practices from 
across North Derbyshire to refer patients for echocardiography. The pilot study operated for 
six months pending evaluation. 
 
Monitoring data for that service suggests that usage has increased markedly over the first 
six months of the year. Use of the service has been evaluated and results show that the 
service is working well and expected outcomes are being achieved. 
 
Analysis of the evaluation forms shows that the management of 52% of the patients has 
changed following echocardiography, with 29% starting a new treatment and 30% stopping 
a previous treatment. Thirteen per cent of the sample are now being referred to a 
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cardiologist whereas 73% would have been had there been no open access 
echocardiography service available. These figures are consistent with the findings in both 
the literature and in other local pilots. 
 
At Stepping Hill, Stockport 32% of patients started a new treatment and 32% stopped an 
existing one compared with 29% starting and 30% stopping at CNDRH. Twenty four per 
cent of the patients at CNDRH stopped being prescribed a diuretic, as did 22% of the 
patients in the Matlock study, and 24% of the patients at Stepping Hill. In Stockport, 64% of 
the patients would have been referred to a cardiologist had there been no open-access 
service, as would 73% of the patients from CNDRH. 
 
Further information, the results from the district-wide audit, and the outcomes in terms of 
patient management from the evaluation of the echocardiography service, are available from 
Mrs Anne Hayes, PACE Project, Public Health Department, North Derbyshire Health 
Authority.  
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APPENDIX 2: Lessons from the Framework for Appropriate Care Throughout 
Sheffield (FACTS) Project 
 
Possible Implementation Strategies: 
 
Left to themselves, different GPs will innovate at different rates, for different levels of risk 
and with different degrees of thoroughness. Given the potential costs and benefits, there are 
strategic advantages in a more coherent and planned implementation of the policy of 
increased use of ACE Inhibitors at a district level. 
 
This appendix outlines how such a planned approach might be created. It incorporates the 
experience of the FACTS project in Sheffield in helping 66 practices in one city prescribe 
aspirin to several thousand patients at high risk of heart attack and stroke. 
 
Developing a District-wide Strategy 
 
Developing a district-wide strategy for the prescription of ACE Inhibitors can be broken down 
into several stages: 
 
a) Creating a clear and credible district-wide policy stating which groups are to be targeted. 
If the intention is to motivate GPs then such a policy must: 
 be clear, coherent and consistent with the evidence. The decision as to which 
patients to target must take account of those groups of patients which practices can 
easily identify (see below);  
 deal explicitly and fairly with the question of prescribing costs. Policies which simply 
expect GPs  to absorb the costs of ACE Inhibitors into their drug budgets could fail. 
 
b) Any  policy, once formulated, is more likely to be effective if it is supported by a coalition 
of key players. Ideally this would include: 
 key local consultants; 
 members of the Local Medical Committee;  
 Director of Public Health; 
 It might also be useful to have the specific endorsement of the Chief Executive of the 
Health Authority for the policy. 
 
 Such coalitions do not necessarily need to include everyone and the experience of the 
FACTS project shows that coalitions are often best negotiated through a series of 
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meetings with individuals rather than trying to get all ‘stakeholders’ together for a single, 
potentially fractious, meeting. 
 
 The purpose of the coalition is to ensure support for the overall principles of the policy, 
and to explore potential problems from the perspectives of different players. It is not to 
develop guidelines or detailed policies about implementation. 
 
c) Given a clear policy endorsed by local consultants, together with an equitable strategy 
for dealing with prescribing costs, most GPs will want to participate. In order to do so 
effectively, practices will need to: 
 identify patients in target groups; 
 pull the notes; 
 exclude those who are contraindicated; 
 invite remaining patients for a consultation and preliminary counselling; 
 prescribe, if appropriate.  
  
d) A whole series of other barriers within practices are likely to arise at this point: 
 workload - few practices have capacity for work that is likely to be seen as ‘extra’ to 
the demands of everyday practice; 
 difficulty identifying target patients; 
 lack of computer skills; 
 concerns about clinical aspects of ACE Inhibitors, side effects etc. 
 
Health Authorities should seriously consider policies to address these difficulties. For 
example: 
 
a) Workload:  
Health Authorities need to recognise this problem explicitly. They can help in two ways: 
 providing concrete help - clear, simple guidelines about what to do; stickers and 
prompts for notes; leaflets for patients; postage for letters; resources. 
 reducing burdens in other areas - offering implementation of the ACE Inhibitor policy 
as an alternative to providing any other health promotion activity and/or banding 
information for the year. 
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b) Identifying target patients: 
There are at least two ways to identify target patients: 
 
 use the practice computer to search for all those on particular drugs, for example, 
diuretics. 
 use the Health Authority database to identify patients who have had a relevant   
diagnosis in hospital and send each practice a list. 
 
 Each of these methods has advantages and disadvantages. These need to be 
understood by those who draw up the district policy - selecting the right mix will be 
crucial if the policy is to be implemented successfully. 
  
c) Computer skills: 
 Although most practices are computerised, the experience of the FACTS project shows 
that many practices have relatively poor IT skills. If implementation of the strategy 
requires anything more than routine computer skills, then many practices will need extra 
help. 
 
d) Concerns about clinical aspects: 
 Many GPs, and practice nurses, will have clinical questions about the use of ACE 
Inhibitors. These need addressing both through continuing medical education (CME) 
meetings and, if possible, with printed material. 
  
Strategies to avoid over-prescription: 
One concern of Health Authorities will be to ensure that people outside the target groups do 
not receive ACE Inhibitors. This might be avoided by giving practices  ‘completion criteria’, 
which would tell them how many people they should have on ACE Inhibitors by the end of 
their implementation process. Such end points could take into account both the demography 
of each practice and/or the prevalence of heart failure. Linking ‘completion criteria’ to cost-
free prescribing (i.e. up to this number of new prescriptions for ACE Inhibitors will be 
discounted from the drug budget) would give a strong message to practices about the 
importance and coherence of the policy, whilst ensuring a cap to ACE Inhibitor costs at a 
district level. 
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APPENDIX 3: Calculations to Support the Analysis of Section 3.3 
 
 
Scenario 1:  If the 921,664 DDD were to be replaced by ramipril  2.5mg – low maintenance regime: 
 
 The cost = 921,664 x £0.189 = £174,194.5 
  
 Therefore potential savings = £341,046 - £ 174,194.5 = £166,851.5 per quarter.  
 i.e. £667,406 per annum. 
 
Scenario 2: If the 921,664 DDD were to be replaced by ramipril  5mg – high  maintenance regime: 
 
 The cost = 921,664 x £0.341 = £314,287  
 Therefore potential savings = £341,046 - £314,287  = £ 26,758 per quarter.  
 i.e. £107,034 per annum 
 
Scenario 3:  If the 921,664 DDD were to be replaced in the same proportions as ramipril  is currently 
prescribed in this population: 
 
 Cost of ramipril  prescribing: 
 3.1% for 1.25mg preparation: Cost per tablet £0.189 
 21.8% for 2.5mg preparation: Cost per tablet £ 0.269 
 75.1% for 5mg preparation:  Cost per tablet £0.341
43
 
  
  NB: 5mg may be prescribed as a double dose i.e. some 5mg prescriptions represent 
10mg daily dosage 
 
For 1.25mg  3.1% x 921,664  EDD
†
 =    28571.6 @ £0.189  =      £5,400 
For 2.5mg    21.9% x 921,664  EDD
†
 =  201844.4 @ £0.269  =    £54,296 
For 5mg   75.1% x 921,664 DDD             = 692169.7 @ £0.341 =  £236,030 
 
†
 EDD = Equivalent Daily Dosage. (E.g. 25mg three times daily is an EDD of 75 mg.) 
 
 Cost of ramipril  prescribing £295,726 
 {at unit prices of 0.38,0.269, 0.17 for 1.25mg, 2.5mg and 5mg respectively = £10,857.2, 
£54,296.1, £117,668.8 = £182,824.1 = savings of £158,221.9 per quarter} 
 
 Therefore potential savings = £341,046 - £295,726 = £45,320 per quarter.  
 i.e. £181,280 per annum 
 
Scenario 4:  If the 921,664 DDD were to be replaced in the same proportions as ramipril  is currently 
prescribed in this population, allowing for 25% of prescriptions being for 10mg daily: 
 
For 1.25mg  3.1% x 921,664 DDD =   28571.58 @ £0.189 =         £5,400 
For 2.5mg    21.9% x 921,664 DDD  = 201844.40 @ £0.269 =       £54,296 
For 5mg   50% x 921,664 DDD =  460832.00@ £0.341 = £157143.70 
 
   
 Cost of ramipril  prescribing for preparations of 5mg or less = £216,839.7 
 Cost of ramipril  5mg twice daily = 25% of 921,664 = 230416 x £0.682 (cost of 2x 5mg 
tablet) = £157,143.7 
 
 Thus, cost of ramipril, allowing for 25% of prescriptions being for 10mg = £373,983 
 
 This is greater than current prescribing costs of £341,046 and, therefore, represents a potential 
extra cost. 
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